Breaking News Bar

Business News and Information

Doctors question FDA approval of Gilead’s COVID-19 treatment and say it has limited benefits

The Food and Drug Administration’s decision to grant a full approval to Gilead Sciences Inc.’s remdesivir is raising questions about the broader value of a drug that has been praised for being ‘first’ but may only provide limited clinical benefits.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
bottom clear